News & Updates

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

FreeStyle Libre system in T2D: Clinical evidence and case studies

11 Jan 2021 by

At a virtual symposium fittingly held on World Diabetes Day, distinguished speakers Dr Eden Miller, Diabetologist, Diplomate of American Board of Obesity Medicine, Executive Director and Co-Founder, Diabetes Nation, Diabetes and Obesity Care, St. Charles Hospital Bend, Oregon, US, and Professor Alice Kong, Endocrinologist, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, shared clinical evidence and case studies on the use of the FreeStyle Libre continuous glucose monitoring (CGM) system in patients with type 2 diabetes (T2D). Dr Lee Lea Im Chua, Family Physician & Director, Bedok Medical Centre, Singapore, chaired this Abbott-sponsored symposium, which was well attended by healthcare professionals from the Asia Pacific region.

FreeStyle Libre system in T2D: Clinical evidence and case studies

11 Jan 2021

HK in CKD: Do diet, HD frequency matter?

28 Jun 2020 by

Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.

HK in CKD: Do diet, HD frequency matter?

28 Jun 2020

Ticagrelor benefits in TWILIGHT hold up in diabetes

23 Apr 2020 by

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Ticagrelor benefits in TWILIGHT hold up in diabetes

23 Apr 2020

News & Updates

Filter by Specialty:

Specialty:

Trimetazidine new formulation redefining angina control in daily practice

Trimetazidine new formulation redefining angina control in daily practice

FreeStyle Libre system in T2D: Clinical evidence and case studies

FreeStyle Libre system in T2D: Clinical evidence and case studies

HK in CKD: Do diet, HD frequency matter?

HK in CKD: Do diet, HD frequency matter?

Ticagrelor benefits in TWILIGHT hold up in diabetes

Ticagrelor benefits in TWILIGHT hold up in diabetes